Copy to clipboard 
Materialise made a strategic investment to acquire a 75% stake in Engimplan, a Brazil-based manufacturer of orthopedic and craniomaxillofacial (CMF) implants and instruments. The combination of Materialise’s expertise in software solutions and services for 3D-printed devices with Engimplan’s product portfolio will help to accelerate the introduction of 3D-printed, personalized implants and instruments in the Brazilian market.
As part of the transaction, Materialise will gain access to Engimplan’s local production facility, expand their portfolio with 3D-printed implants and expertise and enter the company’s existing partner and distribution network in Brazil.
“Surgical planning and 3D printing are increasingly adopted by orthopedic and CMF surgeons, as they understand the positive impact of personalized implants and patient-specific solutions on surgical outcomes”, says Brigitte de Vet, Vice President and General Manager of Materialise Medical. “With this investment, we will expand our medical product and service portfolio, confirming our commitment to strengthen our position and grow our global presence in the medical industry.”
Engimplan’s product offering comprises standard solutions and patient-specific CMF implants that complement Materialise’s product portfolio. Supported by Materialise’s 3D printing experience in developing personalized medical solutions, Engimplan will be able to further expand its product portfolio.
“This investment by Materialise sends a strong signal to our customers and the industry that we remain committed to developing our innovative solutions that improve the lives of many people, and that we have the confidence and support of a pioneer and global leader in 3D printing”, says José Tadeu Leme, CEO of Engimplan. “Together, we can introduce new levels of innovation in the development of personalized implants in Brazil.”
